Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200
Debt
Debt-to-Equity Ratio0.13
Current Ratio2.41
Quick Ratio2.31
Price-To-Earnings
Trailing P/E Ratio-0.14
Forward P/E Ratio-0.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.07 million
Price / Sales1.52
Cash FlowN/A
Price / CashN/A
Book Value$0.61 per share
Price / Book5.57
Profitability
EPS (Most Recent Fiscal Year)($23.72)
Net Income$-21,610,000.00
Net Margins-561.47%
Return on Equity-445.14%
Return on Assets-196.63%
Miscellaneous
Employees95
Outstanding Shares2,270,000
Market Cap$9.14 million
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) released its earnings results on Tuesday, August, 14th. The medical research company reported ($2.70) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($3.30) by $0.60. The medical research company earned $0.82 million during the quarter, compared to the consensus estimate of $1.09 million. Biocept had a negative net margin of 561.47% and a negative return on equity of 445.14%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 brokers have issued twelve-month price targets for Biocept's shares. Their forecasts range from $1.00 to $1.50. On average, they expect Biocept's stock price to reach $1.25 in the next twelve months. This suggests that the stock has a possible downside of 63.2%. View Analyst Price Targets for Biocept.
What is the consensus analysts' recommendation for Biocept?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.
Who are some of Biocept's key competitors?
Some companies that are related to Biocept include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), ELEKTA AB/ADR (EKTAY), Foundation Medicine (FMI), Genomic Health (GHDX), Natera (NTRA), InVitae (NVTA), RadNet (RDNT), CareDx (CDNA), Veracyte (VCYT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN) and Psychemedics (PMD).
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 55)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Sec. (Age 60)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg M.S.E, Associate Director of Technology Devel.
Has Biocept been receiving favorable news coverage?
Press coverage about BIOC stock has been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biocept earned a news and rumor sentiment score of 0.06 on Accern's scale. They also gave media coverage about the medical research company an impact score of 47.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Biocept.
Who are Biocept's major shareholders?
Biocept's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (42.51%) and BlackRock Inc. (34.99%). Company insiders that own Biocept stock include Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Institutional Ownership Trends for Biocept.
Which major investors are selling Biocept stock?
Which major investors are buying Biocept stock?
BIOC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc.. Company insiders that have bought Biocept stock in the last two years include Claire Reiss, David F Hale, Ivor Royston, Lyle J Arnold and Timothy Kennedy. View Insider Buying and Selling for Biocept.
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $3.40.
How big of a company is Biocept?
Biocept has a market capitalization of $9.14 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($23.72) on an earnings per share basis. Biocept employs 95 workers across the globe.
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
